LEO Pharma, which is Denmark’s oldest healthcare company, is setting up a CA$100 million-backed innovation lab in Canada that will develop new, non-pharmaceutical solutions to treat psoriasis, which affects around 125 million people worldwide.

Along the way, the newly formed LEO Innovation Lab will be working with startups to foster innovation in apps, web platforms, wearables, virtual reality, artificial intelligence, tele-medicine and other advanced technologies.

“We know that psoriasis affects many aspects of daily life beyond ones that can be treated with medication,” Miron Derchansky, Head of LEO’s Innovation Lab in Toronto, said in a statement. “LEO Pharma has been developing pharmaceutical products since 1908, and now we’re turning to the digital space and the startup community to help us hack new and creative solutions to help people better manage and deal with their condition.”

Located north of Toronto in Markham, LEO Innovation Lab will focus on areas such as stress, diet, social relationships and healthcare provider interaction. When needed, it will invest in and give grants to startups to help contribute to finding and developing new solutions.

LEO Innovation Lab is LEO Pharma’s first innovation venture outside of Europe. Similar innovation labs operate in Copenhagen, London and Paris.